Literature DB >> 16723091

Effect of nicotinamide on newly diagnosed type 1 diabetic children.

Madeeha Kamal1, Abdul-Jabbar Al Abbasy, Ahood Al Muslemani, Abdulbari Bener.   

Abstract

AIM: To determine whether a low dose of nicotinamide (NA) therapy for pediatric patients with type 1 diabetes, initiated within the first 24 h of diagnosis, prolongs the honeymoon period and lowers their insulin requirements.
METHODS: All children (n=66) with newly diagnosed type 1 diabetes admitted to Salmaniya Medical Complex between 1998 and 2000, received NA 1-2 mg/kg per day, in addition to sc insulin bid. The patients were followed for 24 months (NA group). Findings in this group were compared with records from a similarly diagnosed control group (n=37), who were admitted to the same hospital between 1995 and 1997 and did not receive NA treatment. The insulin dose per kg bodyweight required at baseline and at 3-monthly intervals up to 2 years after diagnosis was determined.
RESULTS: At baseline, the two groups did not differ with respect to age, ethnic background, weight, insulin dose per kg bodyweight or glucose levels on admission. However, NA group had lower insulin requirements than control group at each 3-month interval up to 2 years after diagnosis.
CONCLUSION: Our study results suggest that even low doses of oral NA given to children with newly diagnosed type 1 diabetes may reduce insulin requirements and prolong the honeymoon period.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16723091     DOI: 10.1111/j.1745-7254.2006.00313.x

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  5 in total

1.  Effect of C-peptide Alone or in Combination with Nicotinamide on Glucose and Insulin Levels in Streptozotocin-Nicotinamide-Induced Type 2 Diabetic Mice.

Authors:  Akram Ahangarpour; Fatemeh Ramezani Ali Akbari; Hadi Fathi Moghadam
Journal:  Malays J Med Sci       Date:  2014-07

2.  Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes.

Authors:  Gala Beykin; Laurel Stell; Muhammad Sohail Halim; Mariana Nuñez; Lilia Popova; Bac T Nguyen; Sylvia L Groth; Amy Dennis; Zhongqiu Li; Melissa Atkins; Tom Khavari; Sophia Y Wang; Robert Chang; Ann C Fisher; Yasir J Sepah; Jeffrey L Goldberg
Journal:  Am J Ophthalmol       Date:  2021-11-13       Impact factor: 5.488

3.  Effect of C-peptide Alone or in Combination with Nicotinamide on Insulin Levels from Pancreatic Islets in Mouse.

Authors:  Akram Ahangarpour; Fatemeh Ramezani Ali Akbari; Hadi Fathi Moghadam
Journal:  Malays J Med Sci       Date:  2016-01

Review 4.  Restoring T Cell Tolerance, Exploring the Potential of Histone Deacetylase Inhibitors for the Treatment of Juvenile Idiopathic Arthritis.

Authors:  Lotte Nijhuis; Janneke G C Peeters; Sebastiaan J Vastert; Jorg van Loosdregt
Journal:  Front Immunol       Date:  2019-02-07       Impact factor: 7.561

5.  Case Report: Severe Edema and Marked Weight Gain Induced by Marginal Thiamine Deficiency in a Patient With Alcohol Dependency and Type 2 Diabetes Mellitus.

Authors:  Hitomi Tanaka; Takatoshi Anno; Haruka Takenouchi; Hideyuki Iwamoto; Hideaki Kaneto; Niro Okimoto; Koichi Tomoda
Journal:  Front Nutr       Date:  2021-12-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.